# OnCo record nimotuzumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/nimotuzumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "nimotuzumab" ;
  schema:name "Nimotuzumab"@en ;
  schema:alternateName "h-R3"@en, "BIOMAb EGFR / TheraCIM / CIMAher" ;
  schema:description "Nimotuzumab is a Cuban-developed antibody against EGFR approved in India, China, Cuba and other countries for head and neck cancer, nasopharyngeal cancer and brain tumours, usually with radiotherapy; it causes far less rash than cetuximab but has never been approved in the United States or Europe."@en ;
  schema:url <https://onco.cc/drugs/nimotuzumab/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nimotuzumab> ;
  schema:citation <https://en.wikipedia.org/wiki/Nimotuzumab>, <https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2108574> ;
  onco:status "established" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "Humanised anti-EGFR monoclonal antibody, intravenous" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/kras-wild-type-pdac/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/cetuximab/> ;
  onco:companies <https://onco.cc/companies/cimab/>, <https://onco.cc/companies/biocon/>, <https://onco.cc/companies/eurofarma/> ;
  onco:trials <https://onco.cc/trials/notable-trial/> .